Celltrion Pharm Inc (068760) - Total Liabilities
Based on the latest financial reports, Celltrion Pharm Inc (068760) has total liabilities worth ₩319.38 Billion KRW (≈ $216.44 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 068760 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Celltrion Pharm Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Celltrion Pharm Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Celltrion Pharm Inc balance sheet assets.
Celltrion Pharm Inc Competitors by Total Liabilities
The table below lists competitors of Celltrion Pharm Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Financial Street Holdings Co Ltd
SHE:000402
|
China | CN¥82.27 Billion |
|
Aryzta AG
SW:ARYN
|
Switzerland | CHF1.33 Billion |
|
Imperial Metals Corporation
TO:III
|
Canada | CA$926.35 Million |
|
Shinva Medical Instrument Co Ltd
SHG:600587
|
China | CN¥6.91 Billion |
|
Willis Lease Finance Corporation
NASDAQ:WLFC
|
USA | $2.88 Billion |
|
Kolon Industries Inc
KO:120110
|
Korea | ₩3.75 Trillion |
|
TRUSTPILOT GROUP LS -01
F:6VZ
|
Germany | €134.24 Million |
|
ABOUT YOU Holding AG
F:YOU
|
Germany | €902.70 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Celltrion Pharm Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Celltrion Pharm Inc (068760) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celltrion Pharm Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celltrion Pharm Inc (2011–2024)
The table below shows the annual total liabilities of Celltrion Pharm Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩272.54 Billion ≈ $184.70 Million |
+2.85% |
| 2023-12-31 | ₩264.98 Billion ≈ $179.57 Million |
+9.07% |
| 2022-12-31 | ₩242.94 Billion ≈ $164.64 Million |
-20.59% |
| 2021-12-31 | ₩305.92 Billion ≈ $207.31 Million |
+23.60% |
| 2020-12-31 | ₩247.51 Billion ≈ $167.74 Million |
+29.62% |
| 2019-12-31 | ₩190.95 Billion ≈ $129.40 Million |
+4.68% |
| 2018-12-31 | ₩182.41 Billion ≈ $123.62 Million |
+3.26% |
| 2017-12-31 | ₩176.65 Billion ≈ $119.71 Million |
+6.82% |
| 2016-12-31 | ₩165.37 Billion ≈ $112.07 Million |
-28.27% |
| 2015-12-31 | ₩230.54 Billion ≈ $156.23 Million |
+17.18% |
| 2014-12-31 | ₩196.74 Billion ≈ $133.33 Million |
+1.97% |
| 2013-12-31 | ₩192.94 Billion ≈ $130.75 Million |
+11.01% |
| 2012-12-31 | ₩173.80 Billion ≈ $117.78 Million |
+97.92% |
| 2011-12-31 | ₩87.81 Billion ≈ $59.51 Million |
-- |
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more